30 November 2020
Visiongain has launched a new report RNA Analysis/Transcriptomics Market Report 2020-2030: Forecasts by Type (Microarrays, Polymerase Chain Reaction (PCR), Sequencing Technologies, RNAI Gene Silencing), by Application (Clinical Diagnosis, Drug Discovery, Toxicogenomic), by End-user (Academic Research & Government Institutes, Pharmaceutical & Biotechnology Companies, Hospitals & Diagnostic Centers), by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) PLUS Analysis of Leading Medical Device Contract Manufacturing Companies AND COVID-19 Recovery Scenarios.
Rising preference for personalised medicine in developed as well developing economies coupled with increasing investment by biotechnological and pharmaceutical companies for drug discovery is expected to increase RNA analysis/transcriptomics market concentration over the forecast period. In order to increase the reliability and success rate of the drug production process. RNA sequencing (RNA-Seq) is progressively used for the discovery and profiling of RNA-based drug response biomarkers. Although a variety of tools for this application have been used, the RNA sequencing capabilities promise to be of special value. As a result, there is an increasing need to expand the usability to a wider range of potential users of RNA sequencing related workflow solutions for this use, particularly those without extensive experience with next-generation sequencing (NGS).
Over the past few years, the average number of biotech patent applications has risen at a rate of more than 20 percent annually. More than 1,500 biomolecule-specific studies are ongoing globally at present. In addition, the success rate of studies involving large molecules is almost twice the success rate of small molecule studies. Nearly 13% of biopharmaceutical drugs entering phase I clinical trials are expected to pass all phases of drug production. Increasing research & development spending by biopharmaceutical companies are expected to open new opportunities for RNA analysis industry over the coming years.
The global RNA analysis/transcriptomics market size was dominated by North America in 2019. It was accounted for 39.5% of overall market share in 2019. Presence of well-established pharmaceutical manufacturers followed by increasing preference for personalised medicine is expected to offer potential opportunity for North American RNA analysis/ transcriptomics market over the coming years. However, increasing healthcare infrastructure in developing economies such as India, China, Southeast Asia, Brazil, and Argentina is expected to open avenues for the industry.
The global RNA analysis/transcriptomics market has solid competition amongst the already well-known market players. Also, the industry players are pursuing possible markets to seize a competitive advantage among the other manufacturers operating in this industry by forming mergers & acquisitions, agreements, acquiring other companies, establishing collaboration & partnerships, and growing their business existence. Some prominent companies operating in global RNA analysis/transcriptomics market are Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., GE Healthcare, Illumina, Inc., Qiagen N.V., F. Hoffmann-La Roche Ltd., Sigma-Aldrich Corporation, Thermo Fisher Scientific, Inc., and Fluidigm Corporation.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.
25 November 2022
Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.
25 November 2022
The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.
23 November 2022
The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.